Tongue cancer surgery

Jump to navigation Jump to search

Tongue cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Tongue cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tongue cancer surgery On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tongue cancer surgery

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tongue cancer surgery

CDC on Tongue cancer surgery

Tongue cancer surgery in the news

Blogs on Tongue cancer surgery

Directions to Hospitals Treating Tongue cancer

Risk calculators and risk factors for Tongue cancer surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2] Mohammed Abdelwahed M.D[3]

Overview

Surgery is the mainstay of treatment for tongue cancer. Radical approach is required in larger lesions, impaired tongue mobility, deep tongue infiltration, floor-of-mouth extension. A partial glossectomy with negative margins can preserve speech and swallowing for most stage I and II lesions of the oral tongue. Partial glossectomy is commonly required for advanced disease.Total glossectomy is required in cases where bilateral lingual arteries are involved by cancer. In these cases, postoperative radiotherapy or chemoradiotherapy, appears to improve disease control compared with surgery alone. Elective treatment of the neck in patients with stage I and II oral cavity cancer is not well established. Studies recommend a tumor thickness cutoff of 4 mm as a threshold for elective neck dissection.

Surgery

  • The ideal surgical approach to oral tongue tumors depends on the tumor size and the involvement of adjacent structures.
  • For most small T1 and T2 lesions confined to the tongue, excision is possible with a hemiglossectory or partial hemiglossectomy.
  • Reconstruction of the tongue depends on the size of the defect. When less than a third of the tongue has been resected primary closure is possible.[1]
  • Radical approach is required in:
  • Larger lesions
  • Impaired tongue mobility
  • Deep tongue infiltration
  • Floor-of-mouth extension

Approach

  • The tongue may be approached through a lateral pharyngotomy.
  • A partial glossectomy with negative margins can preserve speech and swallowing for most stage I and II lesions of the oral tongue.
  • Partial glossectomy is commonly required for advanced disease.
  • Total glossectomy is required in cases where bilateral lingual arteries are involved by cancer. In these cases, postoperative radiotherapy or chemoradiotherapy, appears to improve disease control compared with surgery alone.[2]
  • A mandibulotomy may be required for access if the mandible is free of tumor.
  • Consider resection of the mandible in case of tumor involves or extends to the gingiva.
  • Free-flap reconstruction is required for larger defects.
  • Larger lesions which cross the midline are usually not resected due to the operation being poorly tolerated.[3]
  • Total laryngectomy may also be required to prevent aspiration.
  • Assessing surgical resection margins can be difficult. Therefore, close deep surgical margins should be interpreted with caution and more aggressive treatment may be indicated compared with close radial mucosal margins or close margins in other disease sites.

Management of the neck

  • Elective treatment of the neck in patients with stage I and II oral cavity cancer is not well established.[4]
  • Most reports have found that increasing tumor thickness is associated with an increased risk of occult metastases and reduced survival.[5]
  • Studies recommend a tumor thickness cutoff of 4 mm as a threshold for elective neck dissection.[6]
  • The benefit was present in all subgroups, except for those with a primary tumor depth ≤3 mm.
  • An ipsilateral selective neck dissection, levels I to III/IV, for stage I cancers with greater than 3 mm of invasion and for most stage II disease, except minimally invasive primary tumors.
  • Levels IIB and IV are dissected at the discretion of the surgeon.
  • Patients with primary tumors close to or involving the midline should be managed with bilateral neck dissection.[7]
  • Sentinel lymph node biopsy may be an important option between observation and neck dissection in patients with intermediate-thickness tumors.[8]
  • The technique may be most applicable to patients with primary tumors less than 3 mm in depth that have an intermediate risk of lymph node metastasis, and larger primary tumors.
  • A negative sentinel lymph node biopsy may replace planned neck dissection.[9]
  • Brachytherapy can be used in large lesions. The patient is then monitored postoperatively for 48 hours, during which the oncologist proceeds with the brachytherapy dosimetry and implantation of radioactive seeds for periods of up to 72 hours.
  • The needles are then removed and the patient's recovery proceeds in-hospital.
Neck dissection levels, source: modified from Image:Gray385.png modified by Uwe Gille - Image:Gray385.png, Public Domain, https://commons.wikimedia.org/w/index.php?curid=2492547

Video shows glossectomy steps

{{#ev:youtube|t6MFGg_vOkU}}

References

  1. Fujita M, Hirokawa Y, Kashiwado K, Akagi Y, Kashimoto K, Kiriu H; et al. (1996). "An analysis of mandibular bone complications in radiotherapy for T1 and T2 carcinoma of the oral tongue". Int J Radiat Oncol Biol Phys. 34 (2): 333–9. PMID 8567334.
  2. Fein DA, Mendenhall WM, Parsons JT, McCarty PJ, Stringer SP, Million RR; et al. (1994). "Carcinoma of the oral tongue: a comparison of results and complications of treatment with radiotherapy and/or surgery". Head Neck. 16 (4): 358–65. PMID 8056581.
  3. Matsuura K, Hirokawa Y, Fujita M, Akagi Y, Ito K (1998). "Treatment results of stage I and II oral tongue cancer with interstitial brachytherapy: maximum tumor thickness is prognostic of nodal metastasis". Int J Radiat Oncol Biol Phys. 40 (3): 535–9. PMID 9486601.
  4. Bessell A, Glenny AM, Furness S, Clarkson JE, Oliver R, Conway DI; et al. (2011). "Interventions for the treatment of oral and oropharyngeal cancers: surgical treatment". Cochrane Database Syst Rev (9): CD006205. doi:10.1002/14651858.CD006205.pub3. PMID 21901703.
  5. Huang SH, Hwang D, Lockwood G, Goldstein DP, O'Sullivan B (2009). "Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity: a meta-analysis of reported studies". Cancer. 115 (7): 1489–97. doi:10.1002/cncr.24161. PMID 19197973.
  6. D'Cruz AK, Vaish R, Kapre N, Dandekar M, Gupta S, Hawaldar R; et al. (2015). "Elective versus Therapeutic Neck Dissection in Node-Negative Oral Cancer". N Engl J Med. 373 (6): 521–9. doi:10.1056/NEJMoa1506007. PMID 26027881.
  7. Schilling C, Stoeckli SJ, Haerle SK, Broglie MA, Huber GF, Sorensen JA; et al. (2015). "Sentinel European Node Trial (SENT): 3-year results of sentinel node biopsy in oral cancer". Eur J Cancer. 51 (18): 2777–84. doi:10.1016/j.ejca.2015.08.023. PMID 26597442.
  8. Pedersen NJ, Jensen DH, Hedbäck N, Frendø M, Kiss K, Lelkaitis G; et al. (2016). "Staging of early lymph node metastases with the sentinel lymph node technique and predictive factors in T1/T2 oral cavity cancer: A retrospective single-center study". Head Neck. 38 Suppl 1: E1033–40. doi:10.1002/hed.24153. PMID 26040238.
  9. Abdul-Razak M, Chung H, Wong E, Palme C, Veness M, Farlow D; et al. (2017). "Sentinel lymph node biopsy for early oral cancers: Westmead Hospital experience". ANZ J Surg. 87 (1–2): 65–69. doi:10.1111/ans.13853. PMID 27878928.

Template:WH Template:Ws